| DB ID | MyCo_1383 |
| Title | Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes |
| Year | 2018 |
| PMID | 30136398 |
| Fungal Diseases involved | Vulvovaginal candidiasis |
| Associated Medical Condition | Type 2 diabetes |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | The study was approved by the local ethics committee as #251014, and all participants provided written informed con- sent. |
| Site of Infection | Vagina |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Vaginal Fluid |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | SGLT2 inhibitor |
| Biomarker Full Name | Sodium–glucose cotransporter 2 (SGLT2) inhibitor |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | The participants were 114 women with type 2 diabetes who were free of vaginitis symptoms and started SGLT2 inhibitors. Vaginal candidiasis tests through self-administered swabs were carried out at baseline, 6 and 12 months. |
| Cohort No. | 114 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Analytic |
| Analysis Method | Chromoagar-Candida swab analysis |
| ELISA kits | Chromoagar-Candida swab Kit (Kanto Kagaku, Tokyo, Japan) |
| Assay Data | None |
| Validation Techniques used | Chromoagar-Candida swab analysis |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
